The IMAO-B MDL 72.974 A in Parkinson's disease.
作者信息
Marconi R, Bonnet A M, Vidailhet M, Agid Y
出版信息
J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1096-7. doi: 10.1136/jnnp.55.11.1096-a.
Abstract
摘要
相似文献
1
The IMAO-B MDL 72.974 A in Parkinson's disease.帕金森病中的IMAO-B MDL 72.974 A
J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1096-7. doi: 10.1136/jnnp.55.11.1096-a.
2
3
MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.MDL 72,974A：一种具有治疗帕金森病潜力的选择性单胺氧化酶-B抑制剂。
J Neural Transm Suppl. 1993;40:101-11.
4
Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential.单胺氧化酶和半胱胺氧化酶的卤代烯丙胺抑制剂及其治疗潜力。
J Neural Transm Suppl. 1994;41:407-14. doi: 10.1007/978-3-7091-9324-2_54.
5
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].左旋多巴与（-）-司来吉兰治疗帕金森病：一项长期研究[会议论文集]
Br J Pharmacol. 1976 Nov;58(3):423P-424P.
6
MAO-B inhibitors in Parkinson's disease.帕金森病中的单胺氧化酶B抑制剂
Adv Neurol. 1993;60:666-71.
7
Parkinson's disease.帕金森病
Compr Ther. 1986 Mar;12(3):25-9.
8
▼ Safinamide for Parkinson's disease.
Drug Ther Bull. 2018 May;56(5):54-57. doi: 10.1136/dtb.2018.5.0623.
9
[Parkinson's disease].
No To Shinkei. 1994 Mar;46(3):217-27.
10
引用本文的文献
1
Neuroprotective effects of the MAO-B inhibitor, PF9601N, in an in vivo model of excitotoxicity.单胺氧化酶-B抑制剂PF9601N在兴奋性毒性体内模型中的神经保护作用。
CNS Neurosci Ther. 2014 Jul;20(7):641-50. doi: 10.1111/cns.12271. Epub 2014 Apr 28.
本文引用的文献
1
[The L-dopa test in Parkinson's disease].[帕金森病的左旋多巴试验]
Rev Neurol (Paris). 1985;141(5):413-5.
2
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.MDL 72,974：一种强效且选择性的单胺氧化酶B型酶激活不可逆抑制剂，具有用于帕金森病的潜力。
J Neural Transm Park Dis Dement Sect. 1989;1(4):243-54. doi: 10.1007/BF02263478.
3
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Science. 1989 Aug 4;245(4917):519-22. doi: 10.1126/science.2502843.
Zotero 插件